US 11,730,780 B2
Lactic acid bacteria, methods and uses thereof
Stefan Roos, Uppsala (SE)
Assigned to BIOGAIA AB, Stockholm (SE)
Filed by BIOGAIA AB, Stockholm (SE)
Filed on Feb. 14, 2022, as Appl. No. 17/670,968.
Application 17/670,968 is a continuation of application No. 16/496,509, granted, now 11,285,181, previously published as PCT/EP2018/057765, filed on Mar. 27, 2018.
Claims priority of application No. 1750363-2 (SE), filed on Mar. 27, 2017.
Prior Publication US 2022/0168365 A1, Jun. 2, 2022
Int. Cl. A61K 35/747 (2015.01); C12N 1/20 (2006.01); A61K 35/00 (2006.01); C12R 1/225 (2006.01)
CPC A61K 35/747 (2013.01) [C12N 1/205 (2021.05); A61K 2035/115 (2013.01); C12R 2001/225 (2021.05)] 18 Claims
 
1. A method for treating or reducing the risk of developing a condition or disorder caused by or related to an ethanolamine-utilizing pathogen in a subject in need thereof, said method comprising administering to the subject an effective amount of lactic acid bacteria capable of utilizing ethanolamine produced by
(a) culturing in a culture medium lactic acid bacteria that comprises a gene encoding ethanolamine ammonia lyase large subunit EutB, a gene encoding a microcompartment structural protein EutL, and/or a gene encoding an ethanolamine utilization protein EutH and is capable of utilizing ethanolamine;
(b) adding to the culture medium of (a) a first amount or concentration of ethanolamine at a first point in time and growing said culture;
(c) optionally adding to the culture of (b) a second amount or concentration of ethanolamine at a second point in time and growing said culture; and
(d) retrieving the lactic acid bacteria from said culture medium.